Related references
Note: Only part of the references are listed.Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
Marina Macchiagodena et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Nancy H. C. Loos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
Bilal Ahmad et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
No relation between docetaxel administration route and high-grade diarrhea incidence
Jeroen J. M. A. Hendrikx et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4
Mei-Hui Hsu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
Vincent A. de Weger et al.
CLINICAL CANCER RESEARCH (2019)
Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV
Dario Cattaneo et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5
Mei-Hui Hsu et al.
MOLECULAR PHARMACOLOGY (2018)
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates
Ken-ichi Umehara et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2018)
Improved Predictions of Drug–Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A
Jaydeep Yadav et al.
MOLECULAR PHARMACEUTICS (2018)
Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat
Md Amin Hossain et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2017)
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
Ogheneochukome Lolodi et al.
CURRENT DRUG METABOLISM (2017)
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences
Alice Tseng et al.
ANNALS OF PHARMACOTHERAPY (2017)
Evidence-Based Choice of Ritonavir as Index CYP3A Inhibitor in Drug-Drug Interaction Studies
David J. Greenblatt
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
Catia Marzolini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies
David J. Greenblatt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel - a review
Vincent A. de Weger et al.
ANTI-CANCER DRUGS (2014)
Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
J. J. M. A. Hendrikx et al.
BRITISH JOURNAL OF CANCER (2014)
Ritonavir Analogues as a Probe for Deciphering the Cytochrome P450 3A4 Inhibitory Mechanism
Irina F. Sevrioukova et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat
Eve-Irene Lepist et al.
KIDNEY INTERNATIONAL (2014)
Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans
Adam S. Darwich et al.
DRUG METABOLISM AND DISPOSITION (2014)
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database
Emanuel Raschi et al.
WORLD JOURNAL OF HEPATOLOGY (2014)
Analysis of the Pharmacokinetic Boosting Effects of Ritonavir on Oral Bioavailability of Drugs in Mice
Atsuko Tomaru et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Concentration effect relationship of CYP3A inhibition by ritonavir in humans
Christine Eichbaum et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The Effect of Ritonavir on Human CYP2B6 Catalytic Activity: Heme Modification Contributes to the Mechanism-Based Inactivation of CYP2B6 and CYP3A4 by Ritonavir
Hsia-lien Lin et al.
DRUG METABOLISM AND DISPOSITION (2013)
Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro
Eve-Irene Lepist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir
Rachel Puech et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy
S. Katzenmaier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir
Brian J. Kirby et al.
DRUG METABOLISM AND DISPOSITION (2011)
Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir
Brian J. Kirby et al.
DRUG METABOLISM AND DISPOSITION (2011)
Interaction of Eight HIV Protease Inhibitors with the Canalicular Efflux Transporter ABCC2 (MRP2) in Sandwich-cultured Rat and Human Hepatocytes
Zhi-wei Ye et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2010)
Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity
V. Hafner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir
Irina F. Sevrioukova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1
P. Annaert et al.
XENOBIOTICA (2010)
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
Lianhong Xu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Induction effects of ritonavir: Implications for drug interactions
Michelle M. Foisy et al.
ANNALS OF PHARMACOTHERAPY (2008)
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities
E. D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors
Anshul Gupta et al.
DRUG METABOLISM AND DISPOSITION (2008)
A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2008)
Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
R. Scott Obach et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir
KE Culm-Merdek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Mechanism-based inactivation of CYP3A by HIV protease inhibitors
CS Ernest et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats
M Kageyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2)
A Gupta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
RK Zeldin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43
S Krusekopf et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Share Paper
